Company
Product List
Offer to buy
Offer to sell
登入
加入會員
求助
Languages
English
繁體中文
簡體中文
Changchun Changsheng Life Sciences Ltd.
回首頁
公司簡介
產品櫥窗
影音視聽
寄出詢問函
聯絡我們
Recommended Results
Vaccinate Influenza Vaccine For Human
產品分類 :
化學->化學用品->aspalthic products
View Larger Picture
View Larger Picture
View Larger Picture
產品規格
Model No:
0.5ml/Syringe
Country
CN
Minimum Order
5000
Payment Term
L/C,T/T
產品描述
<p class="MsoNormal">
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Drug name</b><b>]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Adopted name: Influenza Vaccine (Split Virion), Inactivated
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Description</b><b>]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. )
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Subsidiary materials: All the components of subsidiary materials approved shall be listed.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Eligibles]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Suscepitable individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Action and use] </b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Specifications</b><b>]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
0. 25 ml or 0.5 ml per container. 0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Administration and dosage</b><b>]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(1) Inject i. m. in the deltoid muscle of the lateral upper arm.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(2) Inoculate before and during the epidemic season of influenza. Inject single human dose of 0.5 ml vaccine for adults and children aged above 3 years. Inject two human doses of 0.25 ml vaccine for children aged between 6 months and 3 years at intervals of 2-4 weeks.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
<b>[Adverse reactions</b><b>]</b><b></b>
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Common adverse reactions
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(1) Pain, tenderness, redness, swelling and itching may occur at the injection sites generally within 24 hours after vaccination, which can be relieved spontaneously within 2-3 days in most cases.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(2) Transient fever may occur a and can be relieved spontaneously within a short period and need no particular treatment in most cases.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Rare adverse reactions
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(1) Transient common cold symptoms and discomfort may occur after vaccination which can be relieved spontaneously and need no particular treatment.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(2) Severe fever: Physical therapy and symptomatic treatment shall be adopted to prevent febrile convulsion.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
Extremely rare adverse reactions
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(1) Allergic rash: Urticaria may occur generally within 72 hours after vaccination, if it occurs the recipients shall go to the clinic promptly and receive anti-anaphylactic treatment.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination, emergency measures shall be adopted immediately including prompt injection of adrenaline.
</p>
<p class="MsoNormal" style="margin-left:0.0000pt;text-indent:0.0000pt;">
(3) Allergic purpura: The recipients with allergic purpura shall go to t.he clinic promptly and receive anti-anaphylactic treatment with corticosteroid. If the treatment is inappropriate or delayed, purpuric nephritis may be complicated.
</p>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<br />
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
<span><strong>[</strong></span><strong>Feature</strong><span><strong>]</strong></span>
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Taking the most advanced influenza producing technology, virus splitting, purification, control tests and specifications are in accordance with WHO standard.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Good vaccine quality, satisfied immunity results, ideal immnunogenicity, high seroconversion rate, anti-body increasing time, all are above the standards set by European Union.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
Special advise: the vaccine should be injected annually.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
1. For adult use in vial and persons aged above 3.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
2. For adult use in pre-filled syringe and persons aged above 3.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
3. For paediatric use in vial aged between 6 months and 35 months.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
4. For paediatric use in pre-filled-syringe aged between 6 months and 35 months.
</p>
<p class="MsoNormal" style="text-align:justify;" align="justify">
</p>
<p class="MsoNormal">
1.influenza vaccine
</p>
<p class="MsoNormal">
2.split virion
</p>
<p class="MsoNormal">
3.WHO recommended strains
</p>
<p class="MsoNormal">
4.against influenza virus
</p>
<p>
<br />
</p>
<span> <img src="http://i.bosscdn.com/product/4b/7c/6b/3e1521af692db14cd8709065d6.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Influenza Vaccine-vial" alt="Influenza Vaccine-vial" /><br />
</span><span><br />
</span>
<p>
<br />
</p>
<p class="MsoNormal">
<span><br />
</span>
</p>
<p class="MsoNormal">
<br />
</p>ccls-vaccine.com
其他類似產品
PFS Varicella Vaccine, Live
Vaccine of wild dog for humans
Inactivated Flu Vaccine for human
Lyophilized Of Rabies Vaccine
[ Back Products Catalog ]
Commerce 會員:
請登入您的 帳號 跟 密碼, 系統將自動為您填入您的相關基本資料!
帳號:
密碼:
記住我的帳號
填寫下列表格並寄送詢問函.所有的詢問信函將會自動寄發給你想聯絡的公司
主旨
內容
﹙ 請勿輸入公司名稱、Email、電話、傳真、網址 ﹚
公司簡介:
*
公司名稱
*
E-mail
*
國家
Please Select Your Country
United States
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaidjan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
Former Czechoslovakia
Former USSR
France
France (European Territory)
French Guyana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Great Britain
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guinea
Guinea Bissau
Guyana
Haiti
Heard and McDonald Islands
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldavia
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
Neutral Zone
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion (French)
Romania
Russian Federation
Rwanda
S. Georgia & S. Sandwich Isls.
Saint Helena
Saint Kitts & Nevis Anguilla
Saint Lucia
Saint Pierre and Miquelon
Saint Tome (Sao Tome) and Principe
Saint Vincent & Grenadines
Samoa
San Marino
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovak Republic
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Taiwan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Vatican City State
Venezuela
Vietnam
Virgin Islands (British)
Virgin Islands (USA)
Wallis and Futuna Islands
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe
*
聯絡人
網址
*
電話
-
-
傳真
-
-
*
郵遞區號
*
城市
*
街道地址
*
企業形態
批發商
出口商
進口商
製造商
大盤商
零售商
代理商
Retrofitter
使用者
其他, 請詳細說明:
*
安全密碼
請輸入所顯示的安全密碼
網站導覽 l
隱私權政策 l
服務團隊 l
合作提案 l
聯絡我們 l
幫幫我 l
廣告刊登 l
B2B商業夥伴
.